These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20607553)

  • 1. Factors influencing disease phenotype and penetrance in HFE haemochromatosis.
    Rochette J; Le Gac G; Lassoued K; Férec C; Robson KJ
    Hum Genet; 2010 Sep; 128(3):233-48. PubMed ID: 20607553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis.
    Merryweather-Clarke AT; Cadet E; Bomford A; Capron D; Viprakasit V; Miller A; McHugh PJ; Chapman RW; Pointon JJ; Wimhurst VL; Livesey KJ; Tanphaichitr V; Rochette J; Robson KJ
    Hum Mol Genet; 2003 Sep; 12(17):2241-7. PubMed ID: 12915468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis.
    Bridle KR; Frazer DM; Wilkins SJ; Dixon JL; Purdie DM; Crawford DH; Subramaniam VN; Powell LW; Anderson GJ; Ramm GA
    Lancet; 2003 Feb; 361(9358):669-73. PubMed ID: 12606179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
    Finberg KE; Whittlesey RL; Andrews NC
    Blood; 2011 Apr; 117(17):4590-9. PubMed ID: 21355094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: Associations in a large community cohort.
    Pilling LC; Atkins JL; Melzer D
    Hepatology; 2022 Dec; 76(6):1735-1745. PubMed ID: 35567766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HFE, hepcidin and ferroportin gene mutations are not present in Indian patients with primary haemochromatosis.
    Shukla P; Julka S; Bhatia E; Shah S; Nagral A; Aggarwal R
    Natl Med J India; 2006; 19(1):20-3. PubMed ID: 16570681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemochromatosis: genetics and pathophysiology.
    Beutler E
    Annu Rev Med; 2006; 57():331-47. PubMed ID: 16409153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical penetrance of C282Y homozygous HFE hemochromatosis.
    Rossi E; Olynyk JK; Jeffrey GP
    Expert Rev Hematol; 2008 Dec; 1(2):205-16. PubMed ID: 21082925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis.
    Piperno A; Girelli D; Nemeth E; Trombini P; Bozzini C; Poggiali E; Phung Y; Ganz T; Camaschella C
    Blood; 2007 Dec; 110(12):4096-100. PubMed ID: 17724144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective release of Hepcidin not defective synthesis is the primary pathogenic mechanism in HFE-Haemochromatosis.
    Arnold J; Sangwaiya A; Bhatkal B; Arnold A
    Med Hypotheses; 2008; 70(6):1197-200. PubMed ID: 18054440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepcidin, a candidate modifier of the hemochromatosis phenotype in mice.
    Nicolas G; Andrews NC; Kahn A; Vaulont S
    Blood; 2004 Apr; 103(7):2841-3. PubMed ID: 14656876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: the genetic basis of haemochromatosis.
    Griffiths WJ
    Aliment Pharmacol Ther; 2007 Aug; 26(3):331-42. PubMed ID: 17635368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele.
    Biasiotto G; Roetto A; Daraio F; Polotti A; Gerardi GM; Girelli D; Cremonesi L; Arosio P; Camaschella C
    Blood Cells Mol Dis; 2004; 33(3):338-43. PubMed ID: 15528154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into iron homeostasis through the study of non-HFE hereditary haemochromatosis.
    Roetto A; Camaschella C
    Best Pract Res Clin Haematol; 2005 Jun; 18(2):235-50. PubMed ID: 15737887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening.
    Barton JC; Acton RT; Leiendecker-Foster C; Lovato L; Adams PC; McLaren GD; Eckfeldt JH; McLaren CE; Reboussin DM; Gordeuk VR; Speechley MR; Reiss JA; Press RD; Dawkins FW;
    Genet Test; 2007; 11(3):269-75. PubMed ID: 17949288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective role of calreticulin in HFE hemochromatosis.
    Pinto JP; Ramos P; de Almeida SF; Oliveira S; Breda L; Michalak M; Porto G; Rivella S; de Sousa M
    Free Radic Biol Med; 2008 Jan; 44(1):99-108. PubMed ID: 18045552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathophysiology and genetics of classic HFE (type 1) hemochromatosis].
    Loréal O; Ropert M; Mosser A; Déhais V; Deugnier Y; David V; Brissot P; Jouanolle AM
    Presse Med; 2007 Sep; 36(9 Pt 2):1271-7. PubMed ID: 17521857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frequency of HFE gene mutations and genotype-phenotype correlations in patients with hereditary hemochromatosis in Switzerland].
    Himmelmann A; Bortoluzzi L; Jansen S; Fehr J
    Schweiz Med Wochenschr; 2000 Aug; 130(31-32):1112-9. PubMed ID: 11008304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HFE hemochromatosis: pathogenic and diagnostic approach].
    Brissot P; Le Lan C; Troadec MB; Lorho R; Ropert M; Lescoat G; Loréal O
    Transfus Clin Biol; 2005 Jun; 12(2):77-82. PubMed ID: 15925529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients.
    McCune CA; Ravine D; Carter K; Jackson HA; Hutton D; Hedderich J; Krawczak M; Worwood M
    Gut; 2006 Apr; 55(4):554-62. PubMed ID: 16174659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.